What are the appropriate drug doses for an 8‑kg child with spinal tuberculosis (Pott’s disease)?

Pediatric Dosing for Pott’s Disease (Spinal TB) at 8 kg

Bold recommendation: Treat an 8‑kg child with drug‑susceptible spinal TB using daily HRZE for 2 months then HR for 4–10 additional months; use weight‑based pediatric doses (H 10 mg/kg, R 15 mg/kg, Z 35 mg/kg, E 15–20 mg/kg) to prioritize neurologic recovery and prevent deformity and relapse 1, 2.

• Regimen selection (drug‑susceptible Pott’s disease):
  • Initial phase (2 months): Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E) daily 2.
  • Continuation phase (at least 4 more months): H + R daily. For spinal/bone TB, extend total duration to 9–12 months if slow clinical/radiographic response or neurologic risk, to reduce relapse and disability 2. Evidence in children supports standard HRZE dosing ranges for safety/efficacy 1, 3, 4.
  • If meningitis suspected, treat as TB meningitis (12 months total, with steroids) 2.

Exact Daily Doses at 8 kg (round to practical formulations)

• Isoniazid (H): 10 mg/kg → 80 mg once daily. Give pyridoxine 25 mg/day with INH to prevent neuropathy 5.
• Rifampin (R): 15 mg/kg → 120 mg once daily 1.
• Pyrazinamide (Z): 35 mg/kg → 280 mg once daily 1.
• Ethambutol (E): 15–20 mg/kg → 120–160 mg once daily; choose 15 mg/kg (120 mg) if vision monitoring is limited; up to 20 mg/kg acceptable per DR‑TB tables when needed 1.
• Duration: 2 months HRZE, then 4 additional months HR minimum; for spinal TB, plan 9–12 months total based on response to minimize morbidity (neurologic compromise, deformity) 2.

Practical dosing (using closest available strengths)

• Common suspensions/tablets vary; aim for:
  • H ≈ 80 mg (e.g., ½ of 150–200 mg scored tablet or syrup).
  • R ≈ 120 mg (e.g., syrup or 150 mg cap opened to measured fraction).
  • Z ≈ 280 mg (round to 250–300 mg based on formulation).
  • E ≈ 120 mg (round to 100–125 mg).
• Recalculate doses with weight gain every 2–4 weeks 2.

Monitoring to protect morbidity, mortality, and QOL

• Baseline and periodic:
  • Hepatotoxicity (H, R, Z): monitor clinically and with ALT if symptomatic; stop all hepatotoxins if hepatitis suspected and re‑introduce stepwise 1.
  • Vision (E): assess color/visual acuity when feasible; stop E if visual symptoms arise 1.
  • Neuropathy: give pyridoxine; increase dose if paresthesias 1.
• Adherence: daily dosing preferred; DOT as feasible 2.

Nuances and caveats

• Ethambutol in young children: acceptable at 15 mg/kg with caution; benefit of four‑drug intensive phase outweighs risk where DR‑TB prevalence is non‑negligible 2, 5.
• TB meningitis or CNS involvement: requires 12 months and adjunctive steroids (to reduce mortality and disability) 2.
• If drug resistance suspected/confirmed, use DR‑TB pediatric dosing tables (e.g., levofloxacin, ethionamide) and specialist input; injectable use, durations differ 1.

Evidence prioritization:

• Pediatric first‑line dosing ranges and safety: most recent high‑quality guideline table endorsing H 10–15 mg/kg, R 10–20 mg/kg, Z 30–40 mg/kg, E 15–25 mg/kg 1.
• Pediatric regimen duration for extrapulmonary (bone/joint) TB: UK/BTS guideline supports standard 6 months for most extrapulmonary sites, with longer courses for meningitis; for spinal disease, clinical caution supports extended duration to reduce relapse and disability 2. Pediatric dosing recalculation and practicalities also supported 2.
• Revised WHO pediatric dose rationale and tolerability support higher R/H/Z targets used above 3, 4.